- Details
- Description
-
Packaging Size100t/bottle
-
Strength50mg
-
CompositonBevantolol hydrochloride
-
TreatmentPrimary hypertensive angina
-
FormTable
-
BrandLuciBev
-
Quantity Unit50mg*100t/Box
-
ManufacturerLucius Pharmaceuticals (Lao) Co.,Ltd
About Bevantolol
Bevantolol (INN) was a drug candidate for angina and hypertension that acted as both a beta blocker and a calcium channel blocker.
Mechanism of action
It selectively blocks cardiac β1 receptors, reducing heart rate and myocardial contractility, and decreasing cardiac output; at the same time, it mildly blocks vascular α1 receptors, dilating peripheral blood vessels. This dual action achieves the effects of lowering blood pressure and relieving angina pectoris, with minimal impact on the bronchi.
Indications
Primary hypertensive angina (stable exertional angina)
Recommended Dosage
Oral: Initially 50 mg twice daily, adjusted according to blood pressure/heart rate, maximum dose 200 mg/day (divided into 2 doses). Elderly patients: Initially 25 mg twice daily, gradually increasing.
Adverse Reactions
Common: Bradycardia (3.2%), dizziness (2.8%), lower extremity edema (1.9%). Serious: Bronchospasm (rare, use with caution in asthmatic patients), worsening of heart failure.
Precautions
Discontinuation requires gradual dose reduction (to avoid rebound hypertension). Blood glucose monitoring is necessary in diabetic patients (may mask symptoms of hypoglycemia). Pregnant women should use only when necessary; contraindicated during lactation.
